摘要
目的:探讨奈达铂联合吉西他滨对卵巢癌患者白细胞下降与Th1、Th2类细胞因子水平的影响。方法:选取2016年10月-2019年10月本院收治的卵巢癌患者124例,应用随机数字表法将其分为研究组和对照组,各62例。两组均进行基础治疗,对照组应用奈达铂治疗,研究组应用奈达铂联合吉西他滨治疗。比较两组患者的治疗效果、不良反应发生情况以及治疗前后Th1、Th2类细胞因子水平。结果:治疗后研究组治疗效果显著优于对照组,且不良反应发生率低于对照组(P<0.05)。治疗前,两组IL-2、IFN-γ、TNF-α、IL-4、IL-6以及IL-10水平比较,差异均无统计学意义(P>0.05);治疗后,研究组IL-2、IFN-γ、TNF-α、IL-4、IL-6以及IL-10水平均显著优于对照组(P<0.05)。结论:卵巢癌患者应用吉西他滨联合奈达铂治疗,效果显著,不仅能降低不良反应的发生率,还可以改善Th1、Th2类细胞因子水平,延缓卵巢癌疾病的进展,值得临床上大力推广。
Objective:To investigate the effects of Nedaplatin combined with Gemcitabine on leukocyte decline and the level of Th1 and Th2 cytokines in patients with ovarian cancer.Method:A total of 124 cases of ovarian cancer patients admitted to our hospital from October 2016 to October 2019 were selected,they were divided into study group and control group by random number table method,62 cases in each group.Both groups received basic treatment,the control group was treated with Nedaplatin,the research group was treated with Nedaplatin combined with Gemcitabine.The therapeutic effect,the incidence of adverse reactions and the levels of Th1 and Th2 cytokines before and after treatment were compared between two groups.Result:After treatment,the therapeutic effect was significantly better than that in the control group,and the incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Before treatment,there were no statistical significance in the levels of IL-2,IFN-γ,TNF-α,IL-4,IL-6 and IL-10 between two groups(P>0.05).After treatment,the levels of IL-2,IFN-γ,TNF-α,IL-4,IL-6 and IL-10 in the study group were significantly higher than those in the control group(P<0.05).Conclusion:Gemcitabine combined with Nedaplatin has a significant effect on ovarian cancer patients,which can not only reduce the occurrence of adverse reactions,but also improve the levels of Th1 and Th2 cytokines and delay the progression of ovarian cancer,which is worthy of great clinical promotion.
作者
刘小立
LIU Xiaoli(Grand Hospital,Jiamusi University,Jiamusi 154000,China)
出处
《中国医学创新》
CAS
2021年第3期81-85,共5页
Medical Innovation of China
